Reviewing Athersys (NASDAQ:ATHX) and Clever Leaves (NASDAQ:CLVR)

Valuation & Earnings

This table compares Athersys and Clever Leaves”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A
Clever Leaves	$17.42 million	0.00	-$17.90 million	($12.36)	N/A

Clever Leaves has higher revenue and earnings than Athersys.

Institutional & Insider Ownership

19.4% of Athersys shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Athersys and Clever Leaves’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Clever Leaves	N/A	N/A	N/A

Risk & Volatility

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, indicating that its share price is 421,186% more volatile than the S&P 500.

Summary

Clever Leaves beats Athersys on 6 of the 8 factors compared between the two stocks.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.